VH-4004280
- Generic Name
- VH-4004280
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
Phase 2
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 43
- Registration Number
- NCT06039579
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 208
- Registration Number
- NCT06012136
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 73
- Registration Number
- NCT05163522
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath